Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: A double-blind, placebo-controlled, crossover trial

Spinal Cord

Volumn 42, Issue 12, 2004, Pages 674-685

  DeForge, D ^a,c   Nymark, J ^b   Lemaire, E ^a,b,c   Gardner, S ^c   Hunt, M ^c   Martel, L ^b   Curran, D ^b   Barbeau, H ^d,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Rehabilitation Centre   (Canada)

^c Rehabilitation Center   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e Jewish Rehab Research Centre   (Canada)

Author keywords

4 aminopyridine; Electromyography; Gait kinematics; Kinetics; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BIOMECHANICS; CANADA; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RELEASE; DYNAMOMETRY; ELECTROMYOGRAPHY; ENERGY EXPENDITURE; FEMALE; GAIT DISORDER; HUMAN; KINEMATICS; LEG MUSCLE; LIVER TOXICITY; MALE; MUSCLE CONTRACTILITY; MUSCLE FORCE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; NAUSEA; NERVE CONDUCTION; OUTCOMES RESEARCH; PARALYSIS; PARAPLEGIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SKIN TINGLING; SPINAL CORD INJURY; STATISTICAL ANALYSIS;

4-AMINOPYRIDINE; ADMINISTRATION, ORAL; ADULT; AGED; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GAIT; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; QUEBEC; REFERENCE VALUES; REHABILITATION CENTERS; RISK ASSESSMENT; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 11244251797     PISSN: 13624393     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.sc.3101653     Document Type: Article

References (34)

1. Waxman SG. Demyelination in spinal cord injury. J Neurol Sci 1989; 91: 1-14.
2. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in spinal cord injury. Brain Res Bull 1989; 22: 47-52.
3. Hayes KC. 4-Aminopyridine and spinal cord injury: a review. Rest Neurol Neurosc 1994; 6: 259-270.
4. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000; 123: 171-184.
5. Kocsis JD, Bowe CM, Waxman SG. Different effects of 4-aminopyridine on sensory and motor fibers: pathogenesis of paresthesias. Neurology 1986; 36: 117-120.
6. van Diemen HM et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993; 116: 220-226.
7. Bever CT. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994; 36: S118-S121.
8. Potter PJ et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998; 36: 147-155.
9. Halter JA, Blight AR, Donovan WH, Calvillo O. Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. Spinal Cord 2000; 12: 728-732.
10. Hayes KC et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993; 31: 216-224.
11. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993; 10: 1-24.
12. Potter PJ et al. Randomized double-blind crossover trial of Fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998; 15: 837-849.
13. Donovan WH et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000; 38: 7-15.
14. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994; 51: 292-296.
15. Segal JL, Brunnemann SR. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med 1998; 21: 200-204.
16. van der Bruggen MA et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001; 248: 665-671.
17. Ditunno JF, Young W, Donovan WH, Greasey G. The international standards booklet for neurological and functional classification of spinal cord injury. Paraplegia 1994; 32: 70-80.
18. Seaby L, Torrance G. Reliability of a physiotherapy functional assessment used in a rehabilitation setting. Physio Can 1989; 41: 264-271.
19. Keppel G. Design and Analysis: a Researcher's Handbook, 3rd edn, Prentice-Hall: NJ, 1991 pp 66-72.
20. Louis T, Lavori P, Bailar J, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med 1984; 310: 24-31.
21. Bohannon R, Larking P, Smith M, Horton M. Relationship between static muscle strength deficits and spasticity in stroke patients with hemiparesis. Phys Ther 1987; 67: 1068-1071.
22. The National Isometric Muscle Strength Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996; 77: 1251-1255.
23. Bäckman E et al. Isometric muscle strength and muscular endurance in normal persons aged between 17 and 70 years. Scand J Rehab Med 1995; 27: 109-117.
24. Bohannon RW. Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil 1997; 78: 26-32.
25. Murray MP, Mollinger LA, Garnder GM, Sepic SB. Kinematic and EMG patterns during slow, free and fast walking. J Orthop Res 1984; 2: 272-280.
26. Öberg T, Karsznia A, berg K. Joint angle parameters in gait: reference data for normal subjects, 10-79 years of age. J Rehabil Res Dev 1994; 31: 199-213.
27. Winter D. The Biomechanics and Motor Control of Human Gait: Normal, Elderly and Pathological. University of Waterloo Press: Waterloo, Canada, 1991.
28. Lemaire ED, Fisher FR, Robertson DGE. Gait patterns of elderly men with trans-tibial amputations. Prosthet Orthot Int 1993; 17: 27-37.
29. Delagi E, Perotto A, Iazetti J, Morrison D. Anatomic Guide for the Electromyographer. Springfield, IL: Charles C. Thomas, 1981.
30. Fung J, Barbeau H. A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait. Electroencephalogr Clin Neurophysiol 1989; 73: 233-244.
31. Qiao J et al. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J Neurotrauma 1997; 14: 135-149.
32. Segal JL et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999; 19: 713-723.
33. Segal JL et al. Absorption characteristics of sustained-release 4-Aminopyridine (Fampridine SR) in patients with chronic spinal cord injury. J Clin Pharmacol 2000; 40: 402-409.
34. Fung J, Stewart JE, Barbeau H. The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects. J Neurol Sci 1990; 100: 85-93.